Showing results (51-60 of 407) with videos related to
Sort By:
Pageof 41
Journal of Hepatology|September 4, 2009
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated ratsThomas Reiberger, Bernhard Angermayr, Philipp Schwabl, et al.European Journal of Clinical Investigation|November 29, 2011
IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patientsBerit A Payer, Thomas Reiberger, Judith Aberle, et al.Plos One|April 12, 2016
Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, AustriaSandra Herout, Mattias Mandorfer, Florian Breitenecker, et al.Hepatology Communications|October 27, 2023
Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib studyEric J Lawitz, Thomas Reiberger, Jörn M Schattenberg, et al.Journal of Hepatology|June 7, 2024
EASL position paper on clinical follow-up after HCV cureThomas Reiberger, Sabela Lens, Giuseppe Cabibbo, et al.Plos One|August 24, 2023
Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomesMichael Schwarz, Caroline Schwarz, Lukas Burghart, et al.Antiviral Therapy|February 7, 2009
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfectionThomas Reiberger, Judith H Aberle, Michael Kundi, et al.Wiener Klinische Wochenschrift|June 16, 2012
Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experienceThomas Reiberger, Arnulf Ferlitsch, Berit Anna Payer, et al.Hepatology International|April 6, 2023
Endoscopic band ligation is safe despite low platelet count and high INRNikolaus Pfisterer, Michael Schwarz, Mathias Jachs, et al.Plos One|April 7, 2023
Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patientsLorenz Balcar, David Bauer, Katharina Pomej, et al.Pageof 41